Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
PR Newswire —
-- Real-world study of AYVAKIT highlights improvement across ISM symptoms -- -- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's leadership in elevating SM care -- CAMBRIDGE, Mass., Feb. 28, 2026 /PRNewswire/ -- Blueprint Medicines, a Sanofi company, today announced...